Questions and Answers

Questions and Answers

1. How high are the dividend payments?

On August 30, 2017, the Annual General Meeting of STADA Arzneimittel AG resolved to distribute a dividend in the amount of EUR 0.72 per share (previous year: 0.70) for financial year 2016 in accordance with the recommendation of the Executive Board and the Supervisory Board.

2. How high were earnings per share (EPS) in recent years?

In EUR 2015 2014 2013 2012 2011 2010 2009 2008 2007
EPS 1.79 1.07 2.04 1.46 0.37 1.16 1.71 1,30 1,79
EPS adjusted* 2.69 3.08 2.70 2.50 2.49 2.27 1.97 1,98 2,48
*Adjusted for one-time special effects

3. When is the next Annual General Meeting?

The next Annual General Meeting will take place on August 30, 2017.

4. How does STADA comply with the Corporate Governance Code?

Click here for the Declaration of Compliance.

5. Which stock market indices include the STADA share?

The STADA share is included on the following indices:

  • MDAX of Deutsche Börse AG since July 2001
  • Dow Jones EuroSTOXXSM 600, which includes 200 European Large, Mid and Small-caps, since
    December 2002
  • MSCI Small Cap Europe since May 30, 2003

Important pharmaceutical indices that include the STADA share include, among others:

  • Bloomberg Pharmaceutical Index (BEPHARM)
  • Dow Jones EuropeanStoxx Healthcare Price Index (SXDE)
  • DJ STOXX Healthcare Price Index (SXDP)
  • Prime Pharma & Healthcare Performance Index (CXPP)

6. When was STADA founded and when was it floated?

STADA was founded as a pharmacists' association in 1895 in Dresden with the name "Standardarzneimittel für deutsche Apotheker". It became a joint stock corporation in 1970 with the initial public offering in 1997. Further milestones you can find here.

7. How can STADA's shareholder structure be broken down?

Click here for a detailed description.

8. What is the outlook?

For the Group’s outlook, the Executive Board generally anticipates continued successful development. Overall, the future sales and earnings development of the Group will be characterized both by growth-stimulating and challenging framework conditions in the individual markets of STADA’s four market regions. In the overall assessment of opposing influence factors, however, the positive prospects are expected to prevail in financial year 2016. In light of this, the Executive Board anticipates slight growth in Group sales adjusted for currency and portfolio effects, adjusted EBITDA as well as adjusted net income in 2016. The Executive Board expects the ratio of net debt excluding further acquisitions to adjusted EBITDA to be at a level of nearly 3. Detailed information on the outlook can be found in the Management Report of the current Annual Report in the chapter “Prognosis report”.

9. Is it possible to receive regular updates about STADA?

This website publishes all the important news about STADA.

Please click here to subscribe to the STADA Newsletter. Enter your email address to automatically receive the latest company news about STADA Arzneimittel AG via email on a regular basis.

Career at STADA

Career at STADA

STADA's employees, with their extensive expertise, their experience and their strong commitment, play an important part in the longstanding success of the Group.

Learn more

Investor Relations

Investor Relations

Here you can find all the facts and background information about the STADA securities.

Lern more



For STADA "All the best" means taking responsibility.

Learn more